Fortress Biotech’s subsidiary, Aevitas Therapeutics, has entered into a sponsored research agreement (“SRA”) with the laboratory of Guangping Gao, Ph.D., at the University of Massachusetts Medical School.    The SRA will evaluate construct optimization in the development of gene therapies based on Aevitas’ adeno-associated virus (“AAV”) technology.   Aevitas also announced the formation of a scientific advisory board and has named Dr. Gao as its first member. Dr. Gao has more tha...